Articles from Actinogen Medical

New academic publication highlights the strong science behind oral Xanamem's brain cortisol-control mechanism

This phase 2b/3, double-blind trial of oral Xanamem in 247 participants with mild to moderate Alzheimer’s disease and elevated pTau181 evaluates the potential benefit of targeting excess cortisol in the brain over a 36-week treatment period

Ongoing Xanamem (emestedastat) Alzheimer’s disease pivotal trial progresses toward final results in November this year

XanaMIA randomized, pivotal trial of oral Xanamem 10 mg fully enrolled and remains on track for topline final results in November 2026

Randomized phase of XanaMIA pivotal trial of oral Xanamem 10 mg remains on track for topline final results in November 2026

XanaMIA trial fully enrolled with final results expected in November 2026

On track for interim analysis in late January 2026 and topline final results November 2026

Current XanaMIA pivotal phase 2/3 trial on track for interim analysis in January 2026 and final results late 2026 with trial enrolment expected to close in Q4 2025

Phase 2b/3 Alzheimer’s trial enrolment expected to reach 100 this quarter, triggering an interim analysis 6 months later